SR vs SHPMY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SR · Spire$88.81 ▼ 0.48%
SHPMY · SHANGHAI PHARMACEU$7.26 ▲ 0.00%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SR +3.2%
- SHPMY -7.7%
Head to head
| Metric | SR | SHPMY |
|---|---|---|
| Price | $88.81 | $7.26 |
| Change today | ▼ 0.48% | ▲ 0.00% |
| Market cap | $5.25B | $5.25B |
| Return, 3 months | +10.7% | -1.8% |
| Return, year to date | +10.6% | -7.7% |
| Return, 1 year | +3.0% | -7.7% |
| P/E (TTM) | 9.9 | 7.2 |
| P/B | 1.5 | 0.5 |
| P/E percentile vs own 5y | 5th | – |
| Dividend yield | 3.67% | 4.57% |
| Revenue growth (YoY, latest qtr) | +19.2% | – |
| Net profit growth (YoY) | +910.5% | – |
| Gross margin | 43.0% | – |
| Operating margin | 21.7% | – |
| Net margin | 19.9% | – |
| Return on equity | 15.6% | – |
| Analyst target vs. price | +1.9% | – |
| Analyst buy share | 50% | – |
| RSI (14) | 68 | 67 |
| 30-day volatility | 18.4% | 31.4% |
| Max drawdown, 1 year | -19.4% | -18.5% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SR is the largest of the group by market value.
- SR has returned the most over the past year.
- SHPMY carries the lowest trailing P/E.
- SHPMY pays the highest dividend yield.
- SR has been the calmest stock over the last 30 days.